Literature DB >> 17705974

Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.

S-W Um1, S W Lee, S Y Kwon, H I Yoon, K U Park, J Song, C-T Lee, J-H Lee.   

Abstract

SETTING: Low serum concentrations of anti-tuberculosis drugs have occasionally been associated with treatment failure.
OBJECTIVE: To determine the prevalence of low serum concentrations of anti-tuberculosis drugs and to identify the determinants of drug concentrations.
DESIGN: Venous blood was obtained 2 h after drug ingestion, and serum levels of isoniazid (INH), rifampicin (RMP), ethambutol (EMB), pyrazinamide (PZA), acetyl INH and 25-desacetyl RMP were analysed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Patients with human immunodeficiency virus co-infection and gastrointestinal disease or diarrhoea were excluded.
RESULTS: Among 69 enrolled TB patients, the prevalence of a low 2 h serum concentration of at least one anti-tuberculosis drug was 46.4%. Prevalences of a low concentration of INH, RMP, EMB or PZA were 15.2%, 23.5%, 22.4% and 4.5%, respectively. By multivariate linear regression analysis, the serum concentrations of INH, RMP and PZA were positively associated with dose per kg of body weight (P < 0.05). Moreover, INH concentration was associated with acetyl INH/INH ratio (beta = -8.588, P < 0.001) and EMB concentration was associated with calculated creatinine clearance (beta = -0.025, P < 0.001).
CONCLUSION: Low concentrations of anti-tuberculosis drugs are common, and although the clinical significance of low concentrations remains uncertain, it may be necessary to optimise drug doses by therapeutic drug monitoring, especially in patients with an inadequate clinical response to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17705974

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  19 in total

Review 1.  Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.

Authors:  Kyle John Wilby; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

2.  Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs.

Authors:  De Socio Giuseppe Vittorio; D'Avolio Antonio; Sgrelli Alessio; Baietto Lorena; Lisa Malincarne; Di Perri Giovanni; Baldelli Franco
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-01-24       Impact factor: 2.576

3.  Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.

Authors:  Geetha Ramachandran; Hemanth Kumar Agibothu Kupparam; Chandrasekaran Vedhachalam; Kannan Thiruvengadam; Vijayalakshmi Rajagandhi; Azger Dusthackeer; Ramesh Karunaianantham; Lavanya Jayapal; Soumya Swaminathan
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets.

Authors:  Laura E Via; Kathleen England; Danielle M Weiner; Daniel Schimel; Matthew D Zimmerman; Emmanuel Dayao; Ray Y Chen; Lori E Dodd; Mike Richardson; Katherine K Robbins; Ying Cai; Dima Hammoud; Peter Herscovitch; Véronique Dartois; JoAnne L Flynn; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

5.  Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Authors:  Erlina Burhan; Carolien Ruesen; Rovina Ruslami; Arum Ginanjar; Hadiarto Mangunnegoro; Purwantyastuti Ascobat; Rogier Donders; Reinout van Crevel; Rob Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

6.  Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.

Authors:  Jong Sun Park; Jae-Yeon Lee; Yeon Joo Lee; Se Joong Kim; Young-Jae Cho; Ho Il Yoon; Choon-Taek Lee; Junghan Song; Jae Ho Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

7.  Analysis of influencing factors on the plasma concentration of first-line anti-tuberculosis drugs-a single-center retrospective cohort study.

Authors:  Guanren Zhao; Ming Chen; Lijun Sun; Na Xi
Journal:  Ann Transl Med       Date:  2022-04

8.  Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection.

Authors:  Claudia Manca; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Gilla Kaplan; Selvakumar Subbian
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

9.  Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.

Authors:  Hendrik Simon Schaaf; Marianne Willemse; Karien Cilliers; Demetre Labadarios; Johannes Stephanus Maritz; Gregory D Hussey; Helen McIlleron; Peter Smith; Peter Roderick Donald
Journal:  BMC Med       Date:  2009-04-22       Impact factor: 8.775

10.  A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.

Authors:  Jin Ah Jung; Tae-Eun Kim; Hyun Lee; Byeong-Ho Jeong; Hye Yun Park; Kyeongman Jeon; O Jung Kwon; Jae-Wook Ko; Rihwa Choi; Hye-In Woo; Won-Jung Koh; Soo-Youn Lee
Journal:  Drug Des Devel Ther       Date:  2015-09-30       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.